Experts share here what they take away from the Conference on Retroviruses and Opportunistic Infections (CROI) each year and ...

One of the hot topics at this year's Conference on Retroviruses and Opportunistic Infections will be long COVID: potential ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

As scientists gathered at the Conference for Retroviruses and Opportunistic Infections, or CROI, for meetings that run through Wednesday, they face an uncertain future. It was evident in who was ...

In 2020, the Conference on Retroviruses and Opportunistic Infections (CROI) was the first scientific conference to move from in-person to virtual due to the COVID-19 pandemic. On the fifth anniversary ...

Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference ...

Severe mpox and long-term sequelae such as severe scarring were more likely to occur among HIV-positive patients with detectable viral loads and low CD4 counts.

Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on ...